C-reactive protein is elevated in obese patients with the metabolic syndrome

Hermes J Florez, Sumaya Castillo-Florez, Armando J Mendez, Paul Casanova-Romero, Carmen Larreal-Urdaneta, David J Lee, Ronald B Goldberg

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

C-reactive protein (CRP) is associated with increased risk for cardiovascular disease and diabetes. Few studies have evaluated the importance of CRP in those with the cluster of cardiovascular risk factors known as the metabolic syndrome (MS). We studied 190 overweight subjects (83 men and 107 women), aged 25-75 years, screened for glucose intolerance, in order to assess whether CRP levels vary according to the presence of MS, and to examine the relationship between CRP levels and metabolic variables. The prevalence of the Adult Treatment Panel III MS was 36.8%. Subjects with the MS had a higher degree of insulin resistance (IR), measured by the homeostasis model assessment (HOMA) method (5.4 ± 0.4 versus 3.6 ± 0.3, p < 0.001) and higher frequency of glucose intolerance (78.3% versus 44.4%, p < 0.001) than those without the MS. CRP values were increased among those with the MS (4.85 ± 0.47 mg/l versus 3.34 ± 0.36 mg/l, p < 0.05). CRP correlated with waist circumference (r = 0.28, p < 0.001) and body mass index (r = 0.38, p < 0.001) in both men and women; however the relationship of CRP with HOMAIR was only evident in men (r = 0.37, p < 0.01) while the association with free fatty acids (FFA) was only significant in women (r = 0.20, p < 0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Abdominal obesity (elevated waist circumference) was the single most important MS component associated with increased CRP levels (>3 mg/dl) (OR = 3.1, 95% C.I.: 1.4-10.1), followed by female gender and smoking. These results confirm that CRP levels are elevated in MS subjects at risk for glucose intolerance. In addition waist circumference, HOMAIR and FFA levels are associated with CRP levels, suggesting potential roles of obesity, insulin resistance and lipolysis in the development of the subclinical inflammation associated with the MS.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume71
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

C-Reactive Protein
Glucose Intolerance
Insulin Resistance
Lipolysis
Waist Circumference
Homeostasis
Cardiovascular Diseases
Obesity
Smoking
Inflammation

Keywords

  • C-reactive protein
  • Free fatty acids
  • Glucose intolerance
  • HOMA-insulin resistance
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

C-reactive protein is elevated in obese patients with the metabolic syndrome. / Florez, Hermes J; Castillo-Florez, Sumaya; Mendez, Armando J; Casanova-Romero, Paul; Larreal-Urdaneta, Carmen; Lee, David J; Goldberg, Ronald B.

In: Diabetes Research and Clinical Practice, Vol. 71, No. 1, 01.01.2006, p. 92-100.

Research output: Contribution to journalArticle

@article{ea2ac97a0ea540f1b9589d2ea86bb522,
title = "C-reactive protein is elevated in obese patients with the metabolic syndrome",
abstract = "C-reactive protein (CRP) is associated with increased risk for cardiovascular disease and diabetes. Few studies have evaluated the importance of CRP in those with the cluster of cardiovascular risk factors known as the metabolic syndrome (MS). We studied 190 overweight subjects (83 men and 107 women), aged 25-75 years, screened for glucose intolerance, in order to assess whether CRP levels vary according to the presence of MS, and to examine the relationship between CRP levels and metabolic variables. The prevalence of the Adult Treatment Panel III MS was 36.8{\%}. Subjects with the MS had a higher degree of insulin resistance (IR), measured by the homeostasis model assessment (HOMA) method (5.4 ± 0.4 versus 3.6 ± 0.3, p < 0.001) and higher frequency of glucose intolerance (78.3{\%} versus 44.4{\%}, p < 0.001) than those without the MS. CRP values were increased among those with the MS (4.85 ± 0.47 mg/l versus 3.34 ± 0.36 mg/l, p < 0.05). CRP correlated with waist circumference (r = 0.28, p < 0.001) and body mass index (r = 0.38, p < 0.001) in both men and women; however the relationship of CRP with HOMAIR was only evident in men (r = 0.37, p < 0.01) while the association with free fatty acids (FFA) was only significant in women (r = 0.20, p < 0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Abdominal obesity (elevated waist circumference) was the single most important MS component associated with increased CRP levels (>3 mg/dl) (OR = 3.1, 95{\%} C.I.: 1.4-10.1), followed by female gender and smoking. These results confirm that CRP levels are elevated in MS subjects at risk for glucose intolerance. In addition waist circumference, HOMAIR and FFA levels are associated with CRP levels, suggesting potential roles of obesity, insulin resistance and lipolysis in the development of the subclinical inflammation associated with the MS.",
keywords = "C-reactive protein, Free fatty acids, Glucose intolerance, HOMA-insulin resistance, Metabolic syndrome, Obesity",
author = "Florez, {Hermes J} and Sumaya Castillo-Florez and Mendez, {Armando J} and Paul Casanova-Romero and Carmen Larreal-Urdaneta and Lee, {David J} and Goldberg, {Ronald B}",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/j.diabres.2005.05.003",
language = "English",
volume = "71",
pages = "92--100",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - C-reactive protein is elevated in obese patients with the metabolic syndrome

AU - Florez, Hermes J

AU - Castillo-Florez, Sumaya

AU - Mendez, Armando J

AU - Casanova-Romero, Paul

AU - Larreal-Urdaneta, Carmen

AU - Lee, David J

AU - Goldberg, Ronald B

PY - 2006/1/1

Y1 - 2006/1/1

N2 - C-reactive protein (CRP) is associated with increased risk for cardiovascular disease and diabetes. Few studies have evaluated the importance of CRP in those with the cluster of cardiovascular risk factors known as the metabolic syndrome (MS). We studied 190 overweight subjects (83 men and 107 women), aged 25-75 years, screened for glucose intolerance, in order to assess whether CRP levels vary according to the presence of MS, and to examine the relationship between CRP levels and metabolic variables. The prevalence of the Adult Treatment Panel III MS was 36.8%. Subjects with the MS had a higher degree of insulin resistance (IR), measured by the homeostasis model assessment (HOMA) method (5.4 ± 0.4 versus 3.6 ± 0.3, p < 0.001) and higher frequency of glucose intolerance (78.3% versus 44.4%, p < 0.001) than those without the MS. CRP values were increased among those with the MS (4.85 ± 0.47 mg/l versus 3.34 ± 0.36 mg/l, p < 0.05). CRP correlated with waist circumference (r = 0.28, p < 0.001) and body mass index (r = 0.38, p < 0.001) in both men and women; however the relationship of CRP with HOMAIR was only evident in men (r = 0.37, p < 0.01) while the association with free fatty acids (FFA) was only significant in women (r = 0.20, p < 0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Abdominal obesity (elevated waist circumference) was the single most important MS component associated with increased CRP levels (>3 mg/dl) (OR = 3.1, 95% C.I.: 1.4-10.1), followed by female gender and smoking. These results confirm that CRP levels are elevated in MS subjects at risk for glucose intolerance. In addition waist circumference, HOMAIR and FFA levels are associated with CRP levels, suggesting potential roles of obesity, insulin resistance and lipolysis in the development of the subclinical inflammation associated with the MS.

AB - C-reactive protein (CRP) is associated with increased risk for cardiovascular disease and diabetes. Few studies have evaluated the importance of CRP in those with the cluster of cardiovascular risk factors known as the metabolic syndrome (MS). We studied 190 overweight subjects (83 men and 107 women), aged 25-75 years, screened for glucose intolerance, in order to assess whether CRP levels vary according to the presence of MS, and to examine the relationship between CRP levels and metabolic variables. The prevalence of the Adult Treatment Panel III MS was 36.8%. Subjects with the MS had a higher degree of insulin resistance (IR), measured by the homeostasis model assessment (HOMA) method (5.4 ± 0.4 versus 3.6 ± 0.3, p < 0.001) and higher frequency of glucose intolerance (78.3% versus 44.4%, p < 0.001) than those without the MS. CRP values were increased among those with the MS (4.85 ± 0.47 mg/l versus 3.34 ± 0.36 mg/l, p < 0.05). CRP correlated with waist circumference (r = 0.28, p < 0.001) and body mass index (r = 0.38, p < 0.001) in both men and women; however the relationship of CRP with HOMAIR was only evident in men (r = 0.37, p < 0.01) while the association with free fatty acids (FFA) was only significant in women (r = 0.20, p < 0.05), even after adjusting for age, hispanic ethnicity and glucose tolerance status. Abdominal obesity (elevated waist circumference) was the single most important MS component associated with increased CRP levels (>3 mg/dl) (OR = 3.1, 95% C.I.: 1.4-10.1), followed by female gender and smoking. These results confirm that CRP levels are elevated in MS subjects at risk for glucose intolerance. In addition waist circumference, HOMAIR and FFA levels are associated with CRP levels, suggesting potential roles of obesity, insulin resistance and lipolysis in the development of the subclinical inflammation associated with the MS.

KW - C-reactive protein

KW - Free fatty acids

KW - Glucose intolerance

KW - HOMA-insulin resistance

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=29244447134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244447134&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2005.05.003

DO - 10.1016/j.diabres.2005.05.003

M3 - Article

VL - 71

SP - 92

EP - 100

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 1

ER -